Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 4;21(1):9. doi: 10.3892/etm.2020.9441

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhou et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Apoptosis of (A) NCI-H661 and (B) NCI-H460 cells was measured by flow cytometry after treatment with a combination of erlotinib and LY294002. The percentage of apoptotic (C) NCI-H661 and (D) NCI-H460 cells was compared between the monotherapy and combined treatment groups. In NCI-H661 cells, a difference in cell apoptosis was detected with the combined drug treatment. Compared with the control, erlotinib (3 µM) or LY294002 (10 µM) treatment alone, the cell apoptosis was significantly enhanced after co-treatment. However, no significantly enhanced apoptosis was observed in the NCI-H460 cell line after co-treatment compared to LY294002 treatment alone. Apoptosis of the erlotinib+LY294002 group was significantly increased compared with the Erlotinib or LY294002 groups. ^*P<0.05 vs. Erlotinib; ^#P<0.05 vs. LY294002.